Testpage/Main 1: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 8: Line 8:


:The ATLAS ACS-TIMI 46 Study Group investigators reported today in ''The Lancet'' that among patients with acute coronary syndromes, the use of oral rivaroxaban therapy was associated with a reduction in rates of major adverse events as well as with a dose-dependent increase in rates of clinically significant bleeding. Two candidate doses were associated with a reduction in the risk of death, MI and stroke, and these two low doses will now be studied in a large event driven phase III trial (ATLAS ACS II-TIMI 51).
:The ATLAS ACS-TIMI 46 Study Group investigators reported today in ''The Lancet'' that among patients with acute coronary syndromes, the use of oral rivaroxaban therapy was associated with a reduction in rates of major adverse events as well as with a dose-dependent increase in rates of clinically significant bleeding. Two candidate doses were associated with a reduction in the risk of death, MI and stroke, and these two low doses will now be studied in a large event driven phase III trial (ATLAS ACS II-TIMI 51).
{{GNews}}
{{GNews}}
|-
|-
|}
|}

Revision as of 20:29, 22 June 2009

WikiDoc News: Today in Medicine

June 17, 2009: Results of the ATLAS ACS-TIMI 46 Study Published in The Lancet

The ATLAS ACS-TIMI 46 Study Group investigators reported today in The Lancet that among patients with acute coronary syndromes, the use of oral rivaroxaban therapy was associated with a reduction in rates of major adverse events as well as with a dose-dependent increase in rates of clinically significant bleeding. Two candidate doses were associated with a reduction in the risk of death, MI and stroke, and these two low doses will now be studied in a large event driven phase III trial (ATLAS ACS II-TIMI 51).

<googlenewsdynamic sites="news.google.com" numresults="30" newstitle="Today in Medicine">newstitle=</googlenewsdynamic>